IBG and Sidra Medicine Sign MoU
IBG and Sidra Medicine Sign MoU
İzmir Biomedicine and Genome Center (IBG) and Sidra Medicine have signed a Memorandum of Understanding (MoU) to strengthen collaboration in pediatric biomedical research. This partnership will focus on key areas such as genomics, precision medicine, biobanking, and stem cell research, enhancing both institutions’ capabilities in addressing critical pediatric health challenges.
Prof. Yılmaz, Director of IBG, highlighted the collaboration’s significance; “By combining our expertise with Sidra Medicine, we can make significant strides in advancing genomic and translational medicine, ultimately improving healthcare outcomes for children worldwide”.
Dr. Iyabo Tinubu-Karch, CEO of Sidra Medicine, emphasized the partnership’s impact; “This MoU is a major step in accelerating genomic discoveries for rare diseases and advancing precision medicine”.
Prof. Khalid Fakhro, Chief Research Officer at Sidra Medicine, also underlined the academic and scientific benefits of the agreement; "Our agreement with IBG will enable student exchanges and visiting scientist programs in both directions between Qatar and Turkey. Additionally, we will establish research cohorts with similar disorders across the MENAT region, helping us gain deeper insights into disease patterns and therapeutic interventions".